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OBJECTIVES: To assess comparative safety and effectiveness of catheter ablation 
(CA) versus surgery in patients with newly diagnosed atrial fibrillation(AF). 
METHODS: We used the national health claim database managed by Health 
Insurance Review and Assessment Service (HIRA) from 2007 to 2011. Patients 
with AF who aged 18-99 were identified using the I48* ICD-10 code. The eligible 
cohort was identified patients who diagnosed new AF in 2008 and treated with 
CA or surgery within 1 year of initial diagnosis. According to modality, 
characteristics of patient were analyzed. Patients were followed until in hospital 
death or December 31, 2011. Mortality and retreatment were analyzed by Cox-
proportion hazard regression. RESULTS: A total of 343 eligible patients with AF 
were composed of 220(82.7%) treated with CA, 123(15.8%) treated with surgery. 
Among treated patients, CHA2DS2 Score were 3.17±1.61 in CA and 4.13±1.67 in 
surgery. Mortality for patients treated with CA and surgery were 0.9% and 10.6% 
respectively, also retreatment rate were 50.9% and 15.4% respectively. Treatment 
modality was associated with retreatment rate of AF[adjusted hazard ratio(HR), 
0.33; 95% confidence interval (CI), 0.18-0.60] and no significant difference in 
mortality. The most common complication was heart failure. CONCLUSIONS: In 
this study, we found that mortality was higher treated with surgery than 
catheter ablation, but there was no significant difference and surgery is 
significantly superior in terms of retreatment rate. However, patients receiving 
catheter ablation therapy are more likely to be at low risk of stroke and follow-up 
time was not enough to compare mortality and complication incidence. 
Therefore, we need additional long-term studies using clinical data of AF.  
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OBJECTIVES: Atrial Fibrillation (AF) is the most common arrhythmia associated 
with a variety of cardiovascular conditions and increased rates of stroke, death. 
The aim of this study was to critically evaluate the current evidence on the use 
of radiofrequency catheter ablation (RFCA) for rhythm control compared with 
antiarrhythmic drug (AAD) therapy in patients with AF. METHODS: We searched 
potentially relevant studies using electronic databases such as Ovid-Medline, 
Ovid-EMBASE, Cochrane library, and seven Korean medical databases through 
May 2012. Two independent reviewers extracted data from each study using a 
standardized form. Disagreements between reviewers were resolved by 
discussion or in consultation with a third reviewer. The quality of the selected 
studies was assessed using the Cochrane risk of bias for randomized controlled 
trials (RCTs). A random-effects model was used to combine trials and the 
dichotomous data were presented as relative risk (RR) with 95% confidence 
intervals (CI). RESULTS: A total of 10 studies (8 RCTs) representing 930 patients 
were included. Their methodological quality was mostly poor. RFCA, in 
comparison with AAD therapy, significantly increased freedom from atrial 
tachycardia/AF (RR 3.06, 95% CI 2.34-3.99, P<0.00001, I2=55%) in 8 RCTs at one year 
follow-up. There was no difference in all-cause mortality (4 RCTs, RR 0.76, 95% CI 
0.18-3.19, P=0.71, I2=0%). Also, the rates of stroke/transient ischemic attack 
between both groups was insignificant (RR 1.95, 95% CI 0.34-11.04, P=0.83, I2=0%). 
Fewer complications were reported in the RFCA group compared with AAD group 
(RR 0.68, 95% CI 0.37-1.23, I2=45%). CONCLUSIONS: There is limited evidence to 
suggest that RFCA may be a better rhythm control treatment option compared  
to AAD therapy in patient with AF. Further rigorous RCTs with long-term  
follow up that overcome the many limitations of the current evidence are 
warranted.  
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OBJECTIVES: Elevated low-density lipoprotein cholesterol (LDL-C) is an 
influential risk factor for cardiovascular disease (CVD) morbidity/mortality. Our 
objective was to evaluate the impact of switches from higher-efficacy lipid-
lowering therapy (HELLT) to simvastatin on LDL-C levels and LDL-C goal 
attainment among high risk patients in UK. METHODS: This retrospective cohort 
study included individuals who received more than 2 months prescription of the 
following HELLT between 8/1/04 and 12/31/08: ezetimibe/simvastatin fixed dose 
combination (E/S), ezetimibe and simvastatin co-administration (E+S), ezetimibe 
and atorvastatin co-administration (E+A), ezetimibe and rosuvastatin co-
administration (E+R), rosuvastatin monotherapy and atorvastatin monotherapy. 
For each baseline HELLT, we used the analysis of covariance to estimate the least 
square mean difference in the percent change from baseline LDL-C between 
switchers and non-switchers, and logistic regression to estimate the odds ratio 
of LDL-C goal attainment (<3mmol/L for primary prevention and <2mmol/L for 
secondary prevention) at follow-up. RESULTS: A totoal of 30,148 patients from 
Clinical Practice Research Datalink met inclusion/exclusion criteria. E+A and E+R 
were excluded due to small number of switchers. 89.1% of switchers in 
atorvastatin group switched to an equivalent or higher efficacy dose of 
simvastatin, while 100% switching from E/S or E+S and 96.8% switching from 
rosuvastatin switched to lower than equivalent efficacy dose. The adjusted least 
squares mean difference of the percent change in LDL-C levels from baseline 
were 18.74% (95% confidence interval 8.6-28.9), 16.7% (12.8-20.6) and -0.1% (-1.8-
1.6) when switching from E/S or E+S, rosuvastatin and atorvastatin respectively 
compared to non-switchers. The odds of LDL-C goal attainment at follow-up for 
E/S or E+S, rosuvastatin and atorvastatin switchers were respectively 0.40 (0.23-
0.70), 0.36 (0.26-0.51) and 1.03 (0.92-1.15) relative to non-switchers. 
CONCLUSIONS: Among the high risk CVD population in the UK, switching to 
simvastatin from higher-efficacy lipid lowering therapy, especially rosuvastatin 
and simvastatin/ezetimibe FDC or co-administration results in higher LDL-C 
level and lower goal attainment rate.  
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OBJECTIVES: To compare cost-effectiveness of two metformin formulations 
(immediate release [IR] and extended release [XR]) in the cohort of patients with 
diabetes mellitus type-2 (DM2) and ischemic heart disease (IHD). METHODS: 
Cost-effectiveness analysis of metformin IR (Siofor® 500 mg tid) and metformin 
XR (Glucophage® Long 750 mg bid) was performed using cohort modeling. Daily 
dosage of metformin was the same for both formulations, 1500 mg a day. For a 
model cohort of 100 patients, annual cost of metformin treatment was 359,270 
RUB (11,841 USD) for metformin IR and 498,347 RUB (16,425 USD) for metformin 
XR. Effectiveness of the treatment was evaluated using the data of UKPDS  
study (1998), which demonstrated that 1% reduction of HbA1c led to 14% 
reduction of angina attacks rate. RESULTS: Assuming linear character of 
relationships between HbA1c level and angina attacks rate, and taking into 
account the data of Donnelly L.A. et al. (2008) that using metformin XR provides 
additional 0.7% reduction of HbA1c level, we suggested that administration of 
metformin XR would reduce the frequency of angina attacks in DM2 patients 
with OHD by 9.8%. It was assumed that average frequency of angina attacks  
in this cohort was 1 per year per patient; therefore administration of metformin 
XR instead of metformin IR would annually prevent approximately 10 cases  
of angina in the modeled cohort of 100 patients. According to standards of  
IHD treatment in Russia, angina attack treatment costs 19,970 RUB per patients 
(658 USD), for 10 patients it will total 199,700 RUB (6,580 USD). This sum might  
be saved by administration of metformin XR, and even taking into account 
higher cost of metformin XR, annual saving per 100 patients would be 60,600  
RUB per year (1,997 USD). CONCLUSIONS: Administration of metformin XR to 
patients with DM2 and IHD is more cost-effective that administration of 
metformin IR.  
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OBJECTIVES: Chronic Heart failure (CHF) is associated with significant morbidity 
and mortality. Angiotensin receptor blockers (ARBs) are one of most commonly 
prescribed drug class for patients with CHF among patients who are intolerant to 
angiotensin converting enzyme inhibitors (ACEI). A recently published Cochrane 
review concluded that ARBs as a class confer no additional benefit on mortality 
or total hospitalization as compared to placebo or ACEI. The aim is to compare 
efficacy of ARBs (losartan, valsartan, candesartan, and telmisartan) on 
hospitalization and mortality relative to each other and to placebo among 
patients with CHF. METHODS: Studies on ARBs were identified from a recently 
published Cochrane systematic review. A network meta-analysis (NMA) was 
conducted for three outcomes; all-cause hospitalizations, hospitalization due to 
heart failure, and all-cause mortality using WinBUGs. Binomial likelihood models 
were run for each outcome and analyses were conducted on an odds ratio scale. 
Fixed or random effects models were run to estimate relative treatment effects 
RESULTS: Sixteen studies were identified from the review. Five studies reported 
data on all-cause hospitalization and six on hospitalizations due to heart failure, 
for two drugs (candesartan and losartan).Data on mortality was reported in 16 
studies for losartan, valsartan, candesartan, and telmisartan. ARBs did not have 
significantly different effects from placebo or each other on all the three 
outcomes studied. NMA can also be used to rank treatments. Within this we 
found that compared to all other ARBs, telmisartan and losartan had the highest 
probabilities of being the best treatments to reduce mortality and 
hospitalizations, respectively. CONCLUSIONS: Results of the NMA indicated that 
there was no significant difference between any of the individual ARBs, ACEI or 
placebo on mortality and hospitalization. A further analysis that uses meta-
regression to adjust for co-morbid conditions such as diabetes, hypertension and 
ischemic heart disease is warranted.  
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OBJECTIVES: To describe methods used and successes realized in building the 
infrastructure to conduct pragmatic clinical trials of comparative effectiveness 
